GPX4 and neoplasm: A novel therapeutic strategy for BRCA1‐deficient tumors is proposed: targeting GPX4‐mediated ferroptosis defense to enhance the sensitivity of Resistance to poly (ADP‐ribose) polymerase inhibitors (PARPi) and overcome tumor resistance to PARPi.